[Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity].
We report a female thalassaemia major patient who developed short stature and osteochondrodystrophic lesions during therapy with desferrioxamine (DFX). Healing was noted after the dose of DFX was decreased for 3 years. Unfortunately the spinal cartilage abnormalities did not change suggesting an irreversibility of the ossification process.
Mangiagli
A
A
Centro Microcitemie, A.O. Umberto I, Siracusa.
De Sanctis
V
V
Campisi
S
S
Di Silvestro
G
G
Urso
L
L
D003676:Deferoxamine / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007502:Iron Chelating Agents / Q000009:adverse effects*; D010009:Osteochondrodysplasias / Q000139:chemically induced*; D013997:Time Factors; D017086:beta-Thalassemia / Q000188:drug therapy*
D007502:Iron Chelating Agents; D003676:Deferoxamine